Current filters:


1 to 9 of 22 results

Resubmission expected for Orexigen's obesity drug Contrave


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

US FDA approves second diet pill, Vivus' Qsymia


In a much anticipated but largely expected decision, the US Food and Drug Administration yesterday approved…

MetabolicsNorth AmericaPharmaceuticalQnexaQsymiaRegulationVivus

EMA agrees more time for Vivus to prepare for Qnexa oral hearings


US drug developer Vivus (Nasdaq: VVUS) says that the European Medicines Agency's Committee for Medicinal…


Vivus says FDA has delayed Qnexa PDUFA date


The US Food and Drug Administration has advised informed USA-based rug developer Vivus (Nasdaq: VVUS)…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

FDA advisory panel backs approval of Qnexa


At last there was finally some good news for drug developer Vivus (Nasdaq: VVUS) - and Americans with…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

FDA updates on obesity drug candidates


There have been two pieces of positive news coming out of the US Food and Drug Administration this week…

Arena PharmaceuticalsEisailorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Vivus findings show greater risk of birth defects with Qnexa ingredient


USA-based drug developer Vivus (Nasdaq: VVUS) has released top-line preliminary results from its retrospective…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationResearchtopiramateVivus

FDA accepts VIVUS NDA filing for Qnexa with PDUFA set for April 2012


There was good news for US drugmaker VIVUS (Nasdaq: VVUS) in its long-running battle to get its weight-loss…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

1 to 9 of 22 results

Back to top